Prostate cancer screening: a new way forward or another false start?

Nature Reviews Urology, Published online: 19 August 2021; doi:10.1038/s41585-021-00513-wSerum PSA testing can identify men with clinically significant prostate cancer but exposes many more men to the diagnosis of indolent tumours. Benafif and colleagues have published the results of the BARCODE1 pilot study, in which they propose using germline single-nucleotide polymorphisms to identify men with a genetic risk of developing prostate cancer. Based on their preliminary findings, changing the current prostate cancer screening paradigm will be a challenge.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research